Dec 9, 2022 · Here we review emerging evidence from recent trials and make some tentative suggestions about which drug is preferable and at what dose in different clinical settings using case …

12 hours ago · What is ponatinib used for? Ponatinib is used for treating resistant CML and Ph+ ALL, particularly in patients with the T315I mutation or multi-TKI resistance.

Dec 1, 2024 · The long-term results from key studies such as ENESTnd, DASISION, and BFORE have helped guide first-line treatment decisions in chronic myeloid leukem…

May 28, 2025 · Treatment of chronic phase (CP) CML generally begins with a BCR::ABL1 TKI, such as imatinib, dasatinib, bosutinib, nilotinib, or asciminib. While their toxicity is generally mild, some …

Jul 17, 2025 · Tyrosine kinase inhibitors (TKIs) revolutionized the CML treatment and helped patients to achieve a higher survival rate. However, TKI resistance, leukemia stem cell (LSC) persistence, and …

Treatment with a frontline BCR-ABL1 tyrosine kinase inhibitor (TKI; e.g., imatinib, dasatinib, and nilotinib) allows patients with chronic myeloid leukemia (CML) in chronic phase (CP) to achieve a ...

Jul 25, 2025 · Several TKI medications are used in CML treatment. Imatinib, a first-generation TKI, was the first approved for CML and remains a common initial treatment option. Second-generation TKIs, …

Jun 27, 2024 · This paper aims to define TKI failure and help guide the selection of second-line treatment after failure of front-line therapy.

Jan 22, 2026 · As evidenced by the excellent survival outcomes, chronic myeloid leukemia treatment in the era of tyrosine kinase inhibitors (TKIs) is often successful. However, when response milestones …

Jul 29, 2024 · Since the introduction of imatinib, five additional TKIs have been approved for CML-CP treatment.